Skip to main content

Table 3 General characteristics of the studies included in the review

From: Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school

Study Objective Type of study No. patients Outcomes
Macedo et al. (2012) [7] To collect current data and evaluate the effect of bevacizumab on first-line therapy, focusing on each backbone regimen; subgroup analysis. Systematic review 3060 PFS and OS
Hurwitz et al. (2013) [17] To describe the results of the analysis of RCTs on bevacizumab in mCRC. The analysis pooled individual patient data from these studies, which allowed a more comprehensive examination of efficacy and safety of bevacizumab. Systematic review 3763 PFS and OS
Saltz et al. (2008) [4] To evaluate the efficacy and safety of bevacizumab when added to oxaliplatin in first-line therapy (capecitabin plus oxaliplatin [XELOX] or fluorouracil/folinic acid plus oxaliplatin [FOLFOX]) in mCRC patients. RCT 1401 PFS and OS
Tournigand et al. (2004) [12] To evaluate FOLFIRI and FOLFOX regimens to determine the best sequence (FOLFIRI or FOLFOX first) to treat mCRC patients. RCT 220 PFS and OS
Van Cutsem et al. (2007) [18] To compare panitumumab plus supportive care versus supportive care in mCRC patients who had progressed after standard chemotherapy. RCT 463 PFS and OS
  1. Abbreviations: XELOX Xeloda® and oxaliplatin, FOLFIRI 5-fluorouracil, leucovorin and irinotecan, FOLFOX 5-fluorouracil, leucovorin and oxaliplatin, RCT randomized, clinical trial, mCRC metastatic colorectal cancer, PFS progression free survival, OS overall survival